837392-69-5

Basic information

• Product Name: 2-Methylbenzo[d]thiazol-6-ylboronic acid pinacol ester
• Synonyms: 2-Methylbenzo[d]thiazol-6-ylboronic acid pinacol ester;2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole
• CAS NO: 837392-69-5
• Molecular Formula: C₁₄H₁₈BNO₂S
• Molecular Weight: 293.1895
• Mol File: 837392-69-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Methylbenzo[d]thiazol-6-ylboronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methylbenzo[d]thiazol-6-ylboronic acid pinacol ester(837392-69-5)
• EPA Substance Registry System: 2-Methylbenzo[d]thiazol-6-ylboronic acid pinacol ester(837392-69-5)

Safety Data

• Hazardous Substances Data: 837392-69-5(Hazardous Substances Data)

Upstream product

• 5304-21-2 6-bromo-2-methylbenzothiazole 
• 73183-34-3 bis(pinacol)diborane 
• 120-75-2 2-Methylbenzothiazole 

Downstream Products

• 2941-71-1 2,6-dimethylbenzothiazole 

Relevant articles and documents

N-HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME

The present invention relates to a novel N-heterocyclic compound and an organic light emitting device comprising the same. When the N-heterocyclic compound according to the present invention is employed as a material for an organic material layer, luminescent properties such as luminous efficiency, power efficiency, quantum efficiency, etc., of the compound induce the increase of light emitting properties, and thus the organic light emitting device having improved power consumption can be realized.

CDK6/DYRK2 Double-target inhibitor as well as preparation method and application thereof

The present invention discloses a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. The invention also discloses a preparation method of the compound and application of the compound in prevention and/or treatment of cancers or tumor-related diseases, especially breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases. The compound provided by the invention is expected to be developed into a new generation of anti-cancer drugs.

Visible Light-Induced Borylation of C-O, C-N, and C-X Bonds

Boronic acids are centrally important functional motifs and synthetic precursors. Visible light-induced borylation may provide access to structurally diverse boronates, but a broadly efficient photocatalytic borylation method that can effect borylation of a wide range of substrates, including strong C-O bonds, remains elusive. Herein, we report a general, metal-free visible light-induced photocatalytic borylation platform that enables borylation of electron-rich derivatives of phenols and anilines, chloroarenes, as well as other haloarenes. The reaction exhibits excellent functional group tolerance, as demonstrated by the borylation of a range of structurally complex substrates. Remarkably, the reaction is catalyzed by phenothiazine, a simple organic photocatalyst with MW 200 that mediates the previously unachievable visible light-induced single electron reduction of phenol derivatives with reduction potentials as negative as approximately - 3 V versus SCE by a proton-coupled electron transfer mechanism. Mechanistic studies point to the crucial role of the photocatalyst-base interaction.